Abeona Therapeutics (ABEO) announced activation of The University of Texas Medical Branch in Galveston, Texas, as the newest Qualified Treatment Center for the administration of Zevaskyn gene-modified cellular sheets. Zevaskyn, a first-of-its-kind, FDA-approved autologous, gene therapy is indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEO:
- Abeona Therapeutics: Promising Growth with ZEVASKYN’s Market Expansion and Strategic Advancements
- Abeona Therapeutics announces first patient treatment with ZEVASKYN
- Abeona Therapeutics reports employee inducement grants
- Optimistic Buy Rating for Abeona Therapeutics Amid Promising ZEVASKYN Outlook and Favorable Market Conditions
- Abeona Therapeutics: Q3 2025 Financial Insights